| abstract |
Disclosed are antagonists designed to inhibit or block the expression of mammalian complement, such as complement component 6 (C6). The present invention has a wide range of applications, including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve injury in mammals. Additional applications include use in the treatment of multiple sclerosis, either alone or in combination with another drug. |